Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Female
| 1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions. |
| 2. Measure serum testosterone and estradiol every 3 mo. |
| a. Serum testosterone levels should be <50 ng/dL. |
| b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL. |
| 3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter. |
| 4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present). |
| 5. Consider BMD testing at baseline (160). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy. |
| 1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions. |
| 2. Measure serum testosterone and estradiol every 3 mo. |
| a. Serum testosterone levels should be <50 ng/dL. |
| b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL. |
| 3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter. |
| 4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present). |
| 5. Consider BMD testing at baseline (160). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy. |
This table presents strong recommendations and does not include lower level recommendations.
Monitoring of Transgender Persons on Gender-Affirming Hormone Therapy: Transgender Female
| 1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions. |
| 2. Measure serum testosterone and estradiol every 3 mo. |
| a. Serum testosterone levels should be <50 ng/dL. |
| b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL. |
| 3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter. |
| 4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present). |
| 5. Consider BMD testing at baseline (160). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy. |
| 1. Evaluate patient every 3 mo in the first year and then one to two times per year to monitor for appropriate signs of feminization and for development of adverse reactions. |
| 2. Measure serum testosterone and estradiol every 3 mo. |
| a. Serum testosterone levels should be <50 ng/dL. |
| b. Serum estradiol should not exceed the peak physiologic range: 100–200 pg/mL. |
| 3. For individuals on spironolactone, serum electrolytes, particularly potassium, should be monitored every 3 mo in the first year and annually thereafter. |
| 4. Routine cancer screening is recommended, as in nontransgender individuals (all tissues present). |
| 5. Consider BMD testing at baseline (160). In individuals at low risk, screening for osteoporosis should be conducted at age 60 years or in those who are not compliant with hormone therapy. |
This table presents strong recommendations and does not include lower level recommendations.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
